RECOMBINANT ANTIBODIES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), OBTAINED BY VARIABLE REGION MUTAGENESIS Russian patent published in 2015 - IPC C07K16/22 

FIELD: medicine.

SUBSTANCE: invention relates to biological chemistry. Described are human recombinant antibodies, which recognise human vascular endothelial growth factor (VEGF-A), block it interaction with receptor VEGFR2, and prevent its proliferative effect in conditions in vitro and proangiogenic effect in conditions in vivo. Antibodies were obtained by combination of variable region of light chain of one immunoglobulin with two other variable regions of heavy chain. Also disclosed are expression vector and nucleic acid, which codes described antibody. Also described is pharmaceutical composition, which contains described antibody.

EFFECT: as antibodies were obtained by mutagenesis of variable region of human immunoglobulin, they can be applied for immunotherapy of pathological forms, associated with increase of vascular net, such as, age-related macular degeneration, malignant neoplasms, etc.

20 cl, 10 dwg, 14 tbl, 16 ex